Drugs / Elravie Re2O
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07155278 | Nov 2024 → May 2025 | skin disorder | Yonsei University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elravie Re2O | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07155278 ↗ |
| Modality | Other / unclassified | “Elravie Re2O is a particulated human Acellular Dermal Matrix (phADM)” NCT07155278 ↗ |